Takeda Canada Announces Topline Results For Phase 3, Randomized, Multicenter, Double-Blind Study Comparing Zasocitinib To Deucravacitinib In Adults With Plaque Psoriasis

Loading news article.

Takeda Canada Announces Topline Results For Phase 3, Randomized, Multicenter, Double-Blind Study Comparing Zasocitinib To Deucravacitinib In Adults With Plaque Psoriasis | WAPE

Takeda Canada Announces Topline Results For Phase 3, Randomized, Multicenter, Double-Blind Study Comparing Zasocitinib To Deucravacitinib In Adults With Plaque Psoriasis

Article summary

Related companies

Comments —